Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 6:47 PM
Ignite Modification Date: 2025-12-24 @ 6:47 PM
NCT ID: NCT00967057
Eligibility Criteria: DISEASE CHARACTERISTICS: * Diagnosis of acute lymphoblastic leukemia (ALL) meeting 1 of the following criteria: * In first relapse after treatment * Has not yet received chemotherapy or radiotherapy for the first relapse * Primary refractory disease * No mature B-cell ALL * Meets criteria for one of the following risk groups: * Standard-risk disease: non-T-cell or T-cell ALL with late isolated extramedullary relapse * Intermediate-risk disease: non-T-cell ALL with early isolated extramedullary relapse or combined marrow and extramedullary relapse; non-T-cell ALL with late combined marrow and extramedullary relapse or isolated marrow relapse; or T-cell ALL with early isolated extramedullary relapse * High-risk disease: non-T-cell ALL with very early isolated extramedullary relapse, combined marrow and extramedullary relapse, or isolated marrow relapse; non-T-cell ALL with early isolated marrow relapse; T-cell ALL with very early isolated extramedullary relapse, combined marrow and extramedullary relapse, or isolated marrow relapse; T-cell ALL with early combined marrow and extramedullary relapse or isolated marrow relapse; or T-cell ALL with late combined marrow and extramedullary relapse or isolated marrow relapse PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior bone marrow transplant
Healthy Volunteers: False
Sex: ALL
Minimum Age: 1 Year
Maximum Age: 18 Years
Study: NCT00967057
Study Brief:
Protocol Section: NCT00967057